Voss A, Seitz C S, Rose C, Bröcker E B, Goebeler M
Klinik und Poliklinik für Haut- und Geschlechtskrankheiten, Universität Würzburg.
Hautarzt. 2001 Oct;52(10):895-8. doi: 10.1007/s001050170056.
Cutaneous angiosarcoma is a rare tumor of endothelial origin, often difficult to diagnose and with an unfavorable prognosis. A 85-year-old woman presented with an extensive angiosarcoma involving her right leg. The tumor was not clinically typical but the diagnosis was confirmed histologically. Because of her age and the extent of the tumor, we elected to treat primarily with cobalt-60 irradiation. The tumor unfortunately progressed during radiation therapy, so we decided to begin palliative chemotherapy with liposome-encapsulated doxorubicin. The patient received six cycles of doxorubicin (Caelyx, 15 mg/m(2) i.v. in four-week intervals) which was well-tolerated and led to complete regression of angiosarcoma which has lasted for 6 months. Chemotherapy with liposome-encapsulated doxorubicin may represent a well-tolerable therapeutic option in cases where surgery and irradiation are not possible or fail. Further studies are necessary to prove the efficacy of doxorubicin therapy in angiosarcoma.
皮肤血管肉瘤是一种罕见的内皮源性肿瘤，通常难以诊断且预后不良。一名85岁女性患者出现累及右腿的广泛性血管肉瘤。该肿瘤在临床上并不典型，但经组织学检查确诊。鉴于她的年龄和肿瘤范围，我们选择主要采用钴-60放疗。不幸的是，肿瘤在放疗期间进展，因此我们决定开始使用脂质体包裹的阿霉素进行姑息化疗。患者接受了六个周期的阿霉素（楷莱，15 mg/m²静脉注射，每四周一次），耐受性良好，血管肉瘤完全消退，持续了6个月。在无法进行手术或放疗或治疗失败的情况下，脂质体包裹的阿霉素化疗可能是一种耐受性良好的治疗选择。需要进一步研究以证实阿霉素治疗血管肉瘤的疗效。
